Elanco Animal Health Incorporated Other Comprehensive Income (Loss), Net of Tax
Elanco Animal Health Incorporated (ELAN) reported Other Comprehensive Income (Loss), Net of Tax of $82.00 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-05-09
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $82.00M, a 256.52% increase year-over-year.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for the quarter ending 2022-12-31 was $615.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$358.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$463.00M, a 377.25% decline year-over-year.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for fiscal 2022 was -$183.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for fiscal 2021 was -$512.00M, a 207.56% decline from fiscal 2020.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for fiscal 2020 was $476.00M, a 871.43% increase from fiscal 2019.
- Elanco Animal Health Incorporated other comprehensive income (loss), net of tax for fiscal 2019 was $49.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | $82.00M 10-Q · filed 2023-05-09 | $697.00M derived: sum of 2 quarters · filed 2023-05-09 | $339.00M derived: sum of 3 quarters · filed 2023-05-09 | -$124.00M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2022-12-31 | $615.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $257.00M derived: sum of 2 quarters · filed 2023-03-01 | -$206.00M derived: sum of 3 quarters · filed 2023-03-01 | -$183.00M 10-K · filed 2023-03-01 | ||||
| 2022-09-30 | -$358.00M 10-Q · filed 2022-11-08 | -$821.00M derived: sum of 2 quarters · filed 2022-11-08 | -$798.00M 10-Q · filed 2022-11-08 | -$861.00M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2022-06-30 | -$463.00M 10-Q · filed 2022-11-08 | -$440.00M 10-Q · filed 2022-08-08 | -$503.00M derived: sum of 3 quarters · filed 2023-05-09 | -$714.00M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2022-03-31 | $23.00M 10-Q · filed 2023-05-09 | -$40.00M derived: sum of 2 quarters · filed 2023-05-09 | -$251.00M derived: sum of 3 quarters · filed 2023-05-09 | -$84.00M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | -$63.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$274.00M derived: sum of 2 quarters · filed 2023-03-01 | -$107.00M derived: sum of 3 quarters · filed 2023-03-01 | -$512.00M 10-K · filed 2023-03-01 | ||||
| 2021-09-30 | -$211.00M 10-Q · filed 2022-11-08 | -$44.00M derived: sum of 2 quarters · filed 2022-11-08 | -$449.00M 10-Q · filed 2022-11-08 | -$25.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $167.00M 10-Q · filed 2022-11-08 | -$238.00M 10-Q · filed 2022-08-08 | $186.00M derived: sum of 3 quarters · filed 2023-03-01 | $279.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | -$405.00M 10-Q · filed 2022-11-08 | $19.00M derived: sum of 2 quarters · filed 2023-03-01 | $112.00M derived: sum of 3 quarters · filed 2023-03-01 | $140.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $424.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $517.00M derived: sum of 2 quarters · filed 2023-03-01 | $545.00M derived: sum of 3 quarters · filed 2023-03-01 | $476.00M 10-K · filed 2023-03-01 | $476.70M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $93.00M 10-Q · filed 2021-11-05 | $121.00M derived: sum of 2 quarters · filed 2021-11-05 | $52.00M 10-Q · filed 2021-11-05 | $51.90M 10-Q · filed 2020-11-06 | $131.30M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $28.00M 10-Q · filed 2021-11-05 | $27.80M 10-Q · filed 2020-07-30 | -$41.00M 10-Q · filed 2021-08-09 | -$41.10M 10-Q · filed 2020-07-30 | $38.30M derived: sum of 3 quarters · filed 2022-02-28 | $600.00K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$69.00M 10-Q · filed 2021-11-05 | -$68.90M 10-Q · filed 2020-05-07 | $10.30M derived: sum of 2 quarters · filed 2022-02-28 | -$27.40M derived: sum of 3 quarters · filed 2022-02-28 | $8.20M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $79.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $41.60M derived: sum of 2 quarters · filed 2022-02-28 | $77.20M derived: sum of 3 quarters · filed 2022-02-28 | $49.00M 10-K · filed 2022-02-28 | $48.50M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | -$37.70M 10-Q · filed 2020-11-06 | -$2.10M derived: sum of 2 quarters · filed 2020-11-06 | -$30.30M 10-Q · filed 2020-11-06 | -$42.20M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $35.60M 10-Q · filed 2020-11-06 | $7.40M 10-Q · filed 2020-07-30 | -$4.50M derived: sum of 3 quarters · filed 2021-03-01 | $90.00M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | -$28.20M 10-Q · filed 2020-11-06 | -$40.10M derived: sum of 2 quarters · filed 2021-03-01 | $54.40M derived: sum of 3 quarters · filed 2021-03-01 | -$168.50M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$11.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $82.60M derived: sum of 2 quarters · filed 2021-03-01 | -$140.30M derived: sum of 3 quarters · filed 2021-03-01 | -$21.70M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $94.50M 10-Q · filed 2019-11-08 | -$128.40M derived: sum of 2 quarters · filed 2019-11-08 | -$9.80M 10-Q · filed 2019-11-08 | -$41.30M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | -$222.90M 10-Q · filed 2019-11-08 | -$104.30M 10-Q · filed 2019-08-13 | -$135.80M derived: sum of 3 quarters · filed 2020-02-28 | -$139.80M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $118.60M 10-Q · filed 2019-11-08 | $87.10M derived: sum of 2 quarters · filed 2020-02-28 | $83.10M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2017-12-31 | -$31.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$35.50M derived: sum of 2 quarters · filed 2020-02-28 | $200.30M 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | -$4.00M 10-Q · filed 2018-11-08 | $231.80M 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | -$235.00M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |